The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective from the Field

Clinical Infectious Diseases

Volumn 62, Issue 1, 2016, Pages 69-74

  Van Griensven, Johan ^a   De Weiggheleire, Anja ^a   Delamou, Alexandre ^b   Smith, Peter G ^c   Edwards, Tansy ^c   Vandekerckhove, Philippe ^d   Bah, Elhadj Ibrahima ^e   Colebunders, Robert ^a,f   Herve, Isola ^g   Lazaygues, Catherine ^g   Haba, Nyankoye ^h   Lynen, Lutgarde ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Centre National de Formation et Recherche en Santé Rurale de Maferinyah   (Guinea)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Rode Kruis Vlaanderen   (Belgium)

^e MÉDECINS SANS FRONTIÈRES   (Switzerland)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g Etablissement Français du Sang   (United States)

^h National Blood Transfusion Center   (Guinea)

Author keywords

clinical trial; convalescent plasma; Ebola; Guinea; therapy

Indexed keywords

ZMAPP; VIRUS ANTIBODY;

ANTIVIRAL THERAPY; CLINICAL EVALUATION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); CONVALESCENT PLASMA; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; FEASIBILITY STUDY; FINANCIAL DEFICIT; FINANCIAL MANAGEMENT; GUINEA; HEALTH CARE UTILIZATION; HUMAN; LIBERIA; NONHUMAN; PATIENT SAFETY; PLASMA TRANSFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIERRA LEONE; SOCIAL ACCEPTANCE; THERAPY EFFECT; VIRUS LOAD; WORLD HEALTH ORGANIZATION; ANIMAL; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE MODEL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; PASSIVE IMMUNIZATION; RHESUS MONKEY;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; EBOLAVIRUS; GUINEA; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION, PASSIVE; MACACA MULATTA;

EID: 84954349613     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ680     Document Type: Review

References (36)

1. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2:695-703.
2. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 2006; 145:599-609.
3. Hsu JL, Safdar N. Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases. Infect Dis Clin North Am 2011; 25:773-88.
4. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J Infect Dis 2015; 211:80-90.
5. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 2010; 38:e66-73.
6. Zhao J, Perera RA, Kayali G, Meyerholz D, Perlman S, Peiris M. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J Virol 2015; 89:6117-20.
7. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979; 2:1216-7.
8. Jahrling PB, Peters CJ. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun 1984; 44:528-33.
9. Jahrling PB, Peters CJ, Stephen EL. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis 1984; 149:420-7.
10. McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314:20-6.
11. Frame JD, Verbrugge GP, Gill RG, Pinneo L. The use of Lassa fever convalescent plasma in Nigeria. Trans R Soc Trop Med Hyg 1984; 78:319-24.
12. World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Interim guidance for national health authorities and blood transfusion services. Geneva, Switzerland: WHO, 2014.
13. World Health Organization. The clinical use of blood handbook. Geneva, Switzerland: WHO, 2002.
14. Jolles S, SewellWA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005; 142:1-11.
15. ClinicalTrials.gov. Putative investigational therapeutics in the treatment of patients with known Ebola infection. 2015. Available at: https://clinicaltrialsgov/ct2/show/ NCT02363322?term=ebola&rank=13.
16. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53.
17. Jahrling PB, Geisbert J, Swearengen JR, et al. Passive immunization of Ebola virusinfected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 1996; 11:135-40.
18. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007; 196(suppl 2):S400-3.
19. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179(suppl 1):S18-23.
20. Sadek RF, Khan AS, Stevens G, Peters CJ, Ksiazek TG. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis 1999; 179(suppl 1):S24-7.
21. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J 1977; 2:541-4.
22. Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014; 371:2402-9.
23. Kraft CS, Hewlett AL, Koepsell S, et al. The Use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis 2015; 61:496-502.
24. World Health Organization. Compassionate use of experimental treatments for Ebola virus disease: outcomes in 14 patients admitted from August to November, 2014. Geneva, Switzerland: WHO, 2015.
25. Burnouf T, Seghatchian J. Ebola virus convalescent blood products: where we are now and where we may need to go. Transfus Apher Sci 2014; 51:120-5.
26. El-Ekiaby M, Vargas M, Sayed M, et al. Minipool caprylic acid fractionation of plasma using disposable equipment: A practical method to enhance immunoglobulin supply in developing countries. PLoS Negl Trop Dis 2015; 9:e0003501.
27. Emergency evaluation of convalescent plasma for Ebola viral disease (EVD) in Guinea (Ebola-Tx). NCT02342171.
28. Clinical trial to evaluate the efficacy and safety of convalescent plasma for Ebola treatment (EVD001). NCT02333578.
29. Adebamowo C, Bah-Sow O, Binka F, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet 2014; 384:1423-4.
30. Mora-Rillo M, Arsuaga M, Ramirez-Olivencia G, et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med 2015.
31. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol 2003; 77:7539-44.
32. Geisbert TW, Hensley LE, Geisbert JB, Jahrling PB. Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections. Virology 2002; 293:15-9.
33. Burnouf T, Emmanuel J, Mbanya D, et al. Ebola: A call for blood transfusion strategy in sub-Saharan Africa. Lancet 2014; 384:1347-8.
34. Bannister-Tyrrell M, Gryseels C, Delamou A, D'Alessandro U, van GJ, Grietens KP. Blood as medicine: social meanings of blood and the success of Ebola trials. Lancet 2015; 385:420.
35. Boahen O, Owusu-Agyei S, Febir LG, et al. Community perception and beliefs about blood draw for clinical research in Ghana. Trans R Soc Trop Med Hyg 2013; 107:261-5.
36. Colebunders RL, Cannon RO. Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease. J Infect Dis 2015; 211:1208-10.